Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Citing clinical trial data that hydroxychloroquine did not show benefits for COVID-19 patients, FDA removes emergency use authorization for the drug as a treatment for the novel coronavirus. 

FDA Revokes EUA for Hydroxychloroquine

Novavax announces DoD contract to produce 10 million doses of COVID-19 vaccine candidate. 

Novavax Secures $60 Million in Government Funds

SiO2 Materials Science has received $143 million from the US government to accelerate capacity scale-up of its advanced primary packaging platform. 

SiO2 Scales Up Container Technology for COVID-19 Vaccines and Treatments

The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.

EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

CordenPharma Expands Lipid Supply for Moderna

Agreements with the PolyPeptide Group and AGC Biologics will scale up production of the Novavax Matrix-M adjuvant.

Novavax Contracts to Expand Adjuvant Production

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

Achieving herd immunity will require testing, data, a vaccine, and public support. 

Are We All In This Together?

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

The correct mix of excipients is crucial to the success of fast dissolving/orally disintegrating dosage forms.

Formulating for Convenience and Compliance

Merck will use Themis’s vector platform to develop a vaccine to prevent COVID-19.

Merck Acquires Themis, Advances SARS-CoV-2 Vaccine Program

Merck will acquire Themis Bioscience and collaborate with IAVI and Ridgeback Bio on COVID-19 vaccines and therapies.